Clinical efficacy and therapy response prediction of neoadjuvant dalpiciclib plus letrozole in postmenopausal patients with HR+/HER2- stage II-III breast cancer (DARLING 01): a single-arm, open-label, exploratory study

Category Primary study
JournalBreast Cancer Res.
Year 2025
This article has no abstract
Epistemonikos ID: 3bc2d1c20a8ebadf88c04e561089fe7decb620d0
First added on: Mar 07, 2025